ReviewNature reviews. Cancer2023
The journey from melanocytes to melanoma.
Review in Nature reviews. Cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 111 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
111 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- New Primary and Secondary Prevention Measures for Cutaneous Melanoma: A Systematic Review.Cancer reports (Hoboken, N.J.) · 2026Pooled it
- Prognostic value of C-reactive protein in patients with melanoma: a meta-analysis.Annals of medicine · 2025Pooled it
- LncRNAEpigenetics · 2026Article
- Pan-Cancer Analysis of the Immunomodulatory Roles and Prognostic Value of PDXP and Experimental Verification in SKCM.Cancer medicine · 2026Article
- PRMT7 restricts CD8+ T cells expansion via the NF-ΚB pathway.Nature communications · 2026Article
- Association between brown adipose tissue activity and clinical outcomes in melanoma: a retrospective PET/CT analysis.Immuno-oncology technology · 2026Article
- Recent Advances in Genetically Engineered Mouse Models of Melanoma: Insights into Tumor Initiation and Oncogenic Signaling Pathways.International journal of stem cells · 2026Review
- Lentiviral hTERT Overexpression Extends the Lifespan of Primary Human Epidermal Melanocytes and Reshapes Transcriptional Programs.Biomolecules · 2026Article
- Targeted therapy in BRAF‑mutant melanoma: Advances and challenges (Review).International journal of oncology · 2026Review
- Computational and Cellular Evaluation of the Anti-Melanogenic Potential of Gancidin W: Integrating Network Pharmacology and Free-Energy Analyses.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Single-cell multimodal profiling of pan-cancer cell lines uncovers gene regulatory principles underlying intrinsic cell states and environmental features.Nature communications · 2026Article
- Interaction of Alkannin with CPEB4 Contributes to Its Antitumor Effects in Melanoma.Biomolecules · 2026Article
- Tumor lymph node metastasis chip reveals that the NECTIN3-TIGIT axis promotes melanoma metastasis by enhancing treg cell function and inducing CD8Cellular oncology (Dordrecht, Netherlands) · 2026Article
- Skin Cells' Protection Against UVA-Induced Changes in Co-Cultured Keratinocytes-Fibroblasts' Proteome and Released Signaling Proteins by 3-International journal of molecular sciences · 2026Article
- Single-cell multimodal profiling of pan-cancer cell lines uncovers gene regulatory principles underlying intrinsic cell states and environmental features.bioRxiv : the preprint server for biology · 2026Article
- Somatic mutations distinguish melanocyte subpopulations in human skin.Nature cell biology · 2026Article
- Review
- Article
- Dynamic Time-Resolved Remodeling of the Immune Microenvironment After Resistance to BRAF/MEK Inhibitors in Melanoma: Mechanisms, Biomarkers, and Emerging Therapeutic Strategies.International journal of molecular sciences · 2026Review
- Multistage responsive microneedle delivery system loaded oncolytic virus for topical therapy of melanoma.Acta pharmaceutica Sinica. B · 2026Article
51 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Over the past decade, melanoma has led the field in new cancer treatments, with impressive gains in on-treatment survival but more modest improvements in overall survival. Melanoma presents heterogeneity and transcriptional plasticity that recapitulates distinct melanocyte developmental states and phenotypes, allowing it to adapt to and eventually escape even the most advanced treatments. Despite remarkable advances in our understanding of melanoma biology and genetics, the melanoma cell of origin is still fiercely debated because both melanocyte stem cells and mature melanocytes can be transformed. Animal models and high-throughput single-cell sequencing approaches have opened new opportunities to address this question. Here, we discuss the melanocytic journey from the neural crest, where they emerge as melanoblasts, to the fully mature pigmented melanocytes resident in several tissues. We describe a new understanding of melanocyte biology and the different melanocyte subpopulations and microenvironments they inhabit, and how this provides unique insights into melanoma initiation and progression. We highlight recent findings on melanoma heterogeneity and transcriptional plasticity and their implications for exciting new research areas and treatment opportunities. The lessons from melanocyte biology reveal how cells that are present to protect us from the damaging effects of ultraviolet radiation reach back to their origins to become a potentially deadly cancer.
Indexed as
Identifiers
37095242What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.